Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1+ BCP-ALL.

Fiedler ERC, Bhutkar A, Lawler E, Besada R, Hemann MT.

Blood Adv. 2018 Jun 12;2(11):1229-1242. doi: 10.1182/bloodadvances.2017015610.

2.

Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.

Chorzalska A, Ahsan N, Rao RSP, Roder K, Yu X, Morgan J, Tepper A, Hines S, Zhang P, Treaba DO, Zhao TC, Olszewski AJ, Reagan JL, Liang O, Gruppuso PA, Dubielecka PM.

Mol Oncol. 2018 May;12(5):630-647. doi: 10.1002/1878-0261.12186. Epub 2018 Apr 6.

3.

Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice.

Xie V, Tong D, Wallington-Beddoe CT, Bradstock KF, Bendall LJ.

Biomark Res. 2018 Feb 5;6:6. doi: 10.1186/s40364-018-0120-4. eCollection 2018.

4.

An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms.

Curto-Garcia N, Harrison CN.

Future Oncol. 2018 Jan;14(2):137-150. doi: 10.2217/fon-2017-0298. Epub 2017 Oct 23.

PMID:
29056075
5.

Transgenic expression of human cytokines in immunodeficient mice does not facilitate myeloid expansion of BCR-ABL1 transduced human cord blood cells.

Askmyr M, von Palffy S, Hansen N, Landberg N, Högberg C, Rissler M, Ågerstam H, Fioretos T.

PLoS One. 2017 Oct 12;12(10):e0186035. doi: 10.1371/journal.pone.0186035. eCollection 2017.

6.

Role of NOX2 for leukaemic expansion in a murine model of BCR-ABL1+ leukaemia.

Grauers Wiktorin H, Nilsson T, Aydin E, Hellstrand K, Palmqvist L, Martner A.

Br J Haematol. 2018 Jul;182(2):290-294. doi: 10.1111/bjh.14772. Epub 2017 May 23. No abstract available.

PMID:
28542840
7.

CML Mouse Model Generated from Leukemia Stem Cells.

Hu Y.

Methods Mol Biol. 2016;1465:27-35. doi: 10.1007/978-1-4939-4011-0_3.

PMID:
27581136
8.

Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.

Mughal TI, Abdel-Wahab O, Rampal R, Mesa R, Koschmieder S, Levine R, Hehlmann R, Saglio G, Barbui T, Van Etten RA.

Leuk Lymphoma. 2016 Jul;57(7):1517-26. doi: 10.1080/10428194.2016.1185783. Epub 2016 May 31. Review.

9.

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T.

Blood. 2016 Apr 28;127(17):2131-43. doi: 10.1182/blood-2015-11-681171. Epub 2016 Feb 10.

10.

Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.

Liang X, Liu X, Wang B, Zou F, Wang A, Qi S, Chen C, Zhao Z, Wang W, Qi Z, Lv F, Hu Z, Wang L, Zhang S, Liu Q, Liu J.

J Med Chem. 2016 Mar 10;59(5):1984-2004. doi: 10.1021/acs.jmedchem.5b01618. Epub 2016 Feb 5.

PMID:
26789553
11.

Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.

Testoni E, Stephenson NL, Torres-Ayuso P, Marusiak AA, Trotter EW, Hudson A, Hodgkinson CL, Morrow CJ, Dive C, Brognard J.

EMBO Mol Med. 2016 Feb 1;8(2):105-16. doi: 10.15252/emmm.201505456.

12.

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

Sadovnik I, Hoelbl-Kovacic A, Herrmann H, Eisenwort G, Cerny-Reiterer S, Warsch W, Hoermann G, Greiner G, Blatt K, Peter B, Stefanzl G, Berger D, Bilban M, Herndlhofer S, Sill H, Sperr WR, Streubel B, Mannhalter C, Holyoake TL, Sexl V, Valent P.

Clin Cancer Res. 2016 Apr 15;22(8):2051-61. doi: 10.1158/1078-0432.CCR-15-0767. Epub 2015 Nov 25.

13.

Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells.

Naka K, Ishihara K, Jomen Y, Jin CH, Kim DH, Gu YK, Jeong ES, Li S, Krause DS, Kim DW, Bae E, Takihara Y, Hirao A, Oshima H, Oshima M, Ooshima A, Sheen YY, Kim SJ, Kim DK.

Cancer Sci. 2016 Feb;107(2):140-8. doi: 10.1111/cas.12849. Epub 2016 Jan 26.

14.

[In vivo "editing'' of cellular genome: one more step toward animals models mimicking tumorigenesis].

Larsen CJ.

Bull Cancer. 2015 Feb;102(2):114-5. French. No abstract available.

PMID:
25874286
15.

Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.

Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh ML, Jung JU, Coligan JE, Bolland S, Mak TW, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA, Müschen M.

Nature. 2015 May 21;521(7552):357-61. doi: 10.1038/nature14231. Epub 2015 Mar 23. Erratum in: Nature. 2016 Jun 2;534(7605):138.

16.

Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.

Askmyr M, Ågerstam H, Lilljebjörn H, Hansen N, Karlsson C, von Palffy S, Landberg N, Högberg C, Lassen C, Rissler M, Richter J, Ehinger M, Järås M, Fioretos T.

Blood Cancer J. 2014 Dec 12;4:e269. doi: 10.1038/bcj.2014.89.

17.

Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer.

Sourbier C, Ricketts CJ, Matsumoto S, Crooks DR, Liao PJ, Mannes PZ, Yang Y, Wei MH, Srivastava G, Ghosh S, Chen V, Vocke CD, Merino M, Srinivasan R, Krishna MC, Mitchell JB, Pendergast AM, Rouault TA, Neckers L, Linehan WM.

Cancer Cell. 2014 Dec 8;26(6):840-850. doi: 10.1016/j.ccell.2014.10.005.

18.

c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity.

Murray JC, Aldeghaither D, Wang S, Nasto RE, Jablonski SA, Tang Y, Weiner LM.

Cancer Immunol Res. 2014 Dec;2(12):1186-98. doi: 10.1158/2326-6066.CIR-14-0083. Epub 2014 Oct 9.

19.

[Establishment of mouse model with humanized Philadelphia chromosome-positive acute lymphoblastic leukemia].

Kong Y, Wang YZ, Hu Y, Huang XJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Feb;22(1):73-7. doi: 10.7534/j.issn.1009-2137.2014.01.016. Chinese.

PMID:
24598655
20.

DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer.

Bailey JM, Alsina J, Rasheed ZA, McAllister FM, Fu YY, Plentz R, Zhang H, Pasricha PJ, Bardeesy N, Matsui W, Maitra A, Leach SD.

Gastroenterology. 2014 Jan;146(1):245-56. doi: 10.1053/j.gastro.2013.09.050. Epub 2013 Oct 2.

Supplemental Content

Loading ...
Support Center